Uncontrolled Gout: A Ticking Time Bomb for Kidney Health and Longevity
Gout patients, beware! New research reveals a startling connection between uncontrolled gout (UCG) and severe health consequences. In a study to be presented at the 2025 American Society of Nephrology Kidney Week, Zhang and colleagues uncover a heightened risk of kidney failure, chronic kidney disease (CKD), and mortality in patients with UCG compared to those with controlled gout (CG).
Gout, a painful form of arthritis, has long been associated with kidney damage due to urate buildup and inflammation. However, the impact of uncontrolled gout on kidney health has remained largely unexplored until now. And this is where it gets intriguing...
The researchers conducted a retrospective study, analyzing real-world data from 2016 to 2024, excluding patients with any stage of CKD. They compared UCG and CG patients across three critical outcomes: renal failure, CKD, and death. But here's the twist: they defined CG as patients with no flares, no visible tophi, and normal serum urate (SU) levels below 6 mg/dL for at least 3 months before the study.
The study revealed a stark contrast in health outcomes. Patients with UCG were generally younger, predominantly male, and had higher rates of obesity (24% vs 10%) and hypertension (63% vs 39%) compared to the CG group. When it came to the combined CKD and renal failure cohorts, a staggering 13,736 patients had UCG, and in the mortality cohort, 21,292 patients were affected by UCG.
The numbers don't lie: UCG was linked to a significantly higher risk of renal failure (77 vs 27 events per 1,000 person-years), almost double the rate of new CKD cases (101 vs 58 events per 1,000 person-years), and increased mortality (60 vs 42 events per 1,000 person-years) compared to CG.
The researchers emphasize the importance of these findings, suggesting that improved gout control could be a powerful tool in safeguarding kidney health and reducing mortality. But this raises a question: are we doing enough to manage gout effectively?
Note: This study received commercial support from Amgen.
